Dendritic cell cancer vaccines: from the bench to the bedside
/in Dendritic Cells, International Publications /von 2014-10-29 / Rambam Maimonides Med J 2014 Oct;5(4):e0024IOZK Fallstudie über die erfolgreiche Behandlung eines metastasierten Prostatakarzinoms
/in IOZK Veröffentlichungen /von IOZKOverexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2014-10-21 / J. Cell. Mol. Med. 2015 Feb;19(2):340-50Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2014-10-18 / Expert Opin Biol Ther 2015 Jan;15(1):79-94Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro
/in International Publications, Newcastle Disease Virus, NSCLC /von 2014-10-15 / Mol Med Rep 2015 Jan;11(1):317-26Inhibition of cell proliferation by mild hyperthermia at 43˚C with Paris Saponin I in the lung adenocarcinoma cell line PC-9
/in Hyperthermia, International Publications, NSCLC /von 2014-10-15 / Mol Med Rep 2015 Jan;11(1):327-32Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care
/in Hyperthermia, International Publications /von 2014-10-07 / Semin. Oncol. 2014 Dec;41(6):714-29Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
/in Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus, Prostate Cancer /von 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2014-10-06 / Int. J. Oncol. 2015 Jan;46(1):71-7
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution